

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2004

The World Health Organization monitors the tuberculosis epidemic, evaluating surveillance, planning, and financial data in support of national TB control programmes.

For further information about tuberculosis or other communicable diseases, please contact

Information Resource Centre
CDS-HTM
World Health Organization
20 Avenue Appia • CH-1211 Geneva 27 • Switzerland

fax +41 22 791 4285
tuberculosis@who.int

You can also visit our website at
<http://www.who.int/gtb>


ISBN 92 4 156264 1



WHO REPORT 2004

Global Tuberculosis Control

Surveillance, Planning, Financing



WORLD HEALTH ORGANIZATION
GENEVA

WHO REPORT 2004

Global Tuberculosis Control

Surveillance, Planning, Financing



WORLD HEALTH ORGANIZATION
GENEVA

WHO Library Cataloguing-in-Publication Data

World Health Organization.

Global tuberculosis control : surveillance, planning, financing : WHO report 2004.

1.Tuberculosis, Pulmonary – prevention and control 2.Tuberculosis, Multidrug-resistant – drug therapy
4.Directly observed therapy 5.Treatment outcome 6.National health programs – organization and
administration 7.Financing, Health 7.Statistics I.Title.

ISBN 92 4 156264 1

(NLM classification: WF 300)

WHO/HTM/TB/2004.331

Suggested citation

World Health Organization. *Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004*. Geneva, Switzerland, ISBN 92 4 156264 1.

© WORLD HEALTH ORGANIZATION 2004

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to Publications, at the above address (fax: +41 222 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

The named authors alone are responsible for the views expressed in this publication.

Cover: The image depicts progress towards the principal WHO targets of 70% TB case detection and 85% treatment success, which should be achieved by 2005. The smear-positive case detection rate was estimated to be 37% in 2002 (green line), and accelerating. The treatment success (blue bars) was 82% in the 2001/2 cohort. To reach case detection rates above 50%, national TB control programmes employing the DOTS strategy must expand their services beyond the present limits of public health systems.

Designed by minimim graphics
Printed in Switzerland

Contents

Acknowledgements	v
Abbreviations	vii
Summary	
English	1
French	4
Spanish	7
Introduction	10
Methods	11
Monitoring the detection and treatment of TB cases	11
Data collection	11
Data verification	11
DOTS classification	11
Presentation of data	11
Calculation of indicators	12
Estimation of TB incidence	12
Case detection	13
Treatment success	13
DOTS population coverage	13
Planning and DOTS implementation	14
Planning activities carried out in 2003	14
Update of country profiles	14
Constraints and remedial actions	15
Partnerships and coordination	15
Planning for MDR-TB control	15
Collaborative TB/HIV activities	15
Financing DOTS expansion	15
Background and objectives	15
Data collection	16
Data analysis: high-burden countries	16
Data analysis: other countries	17
Results	18
Detection and treatment of TB cases	18
Countries reporting to WHO	18
DOTS population coverage, 1995–2002	18
Case notifications, 1995–2002	18

Case detection rate, 1995–2002	25
Treatment results, 1994–2001 cohorts	27
Progress towards targets for case detection and treatment success	29
Planning and DOTS implementation	32
Constraints and remedial actions	32
Partnerships and coordination	34
Planning for MDR-TB control	35
Collaborative TB/HIV activities	35
Financing DOTS expansion	35
Countries reporting to WHO	35
NTP budgets, total costs of TB control, and government contributions among HBCs, 2002 and 2003	35
Funding sources and gaps for fiscal year 2003 in high-burden countries	38
GFATM contribution to TB control in 2003	41
Resources required for TB control in high-burden countries, 2004 and 2005	41
NTP budgets and funding gaps in other countries	43
Discussion	44
Detection and treatment of TB cases	44
Planning and DOTS implementation	45
Financing DOTS expansion	46
Annex 1 Profiles of high-burden countries	49
Annex 2 Country data by region	127
Explanatory notes for the country data	129
Africa	131
The Americas	143
Eastern Mediterranean	155
Europe	167
South-East Asia	179
The Western Pacific	191
Annex 3 Comparison of cases notified and registered for treatment under DOTS in 2001	203
Annex 4 Trends in treatment success and DOTS detection rates, 1994–2002	207
Annex 5 World maps	213
1. Estimated TB incidence rates, 2002	215
2. Estimated HIV prevalence in TB cases, 2002	216
3. Implementation of DOTS, 2002	217
4. Tuberculosis notification rates, 2002	218

Acknowledgements

This report was written by Léopold Blanc, Daniel Bleed, Christopher Dye, Katherine Floyd, Christy Hanson, Mehran Hosseini, Karen Palmer, and Catherine Watt. The project was coordinated by Christopher Dye and Léopold Blanc.

Other WHO staff who assisted in compiling information were as follows:

WHO HQ Geneva: Mohammed Aziz, Marcos Espinal, Giuliano Gargioni, Haileyesus Getahun, Andrea Godfrey, Malgosia Grzemska, Knut Lönnroth, Eva Nathanson, Paul Nunn, Salah Ottmani, Mario Raviglione, Holger Sawert, Mukund Uplekar, Lisa Véron, Brian Williams, Abigail Wright.

African Region: Ayodele Awe (Nigeria), Panganai Dhliwayo (Zimbabwe), Jan van den Hombergh (Ethiopia), Bah Keita (AFRO, West Africa), Daniel Kibuga (AFRO), Vainess Mfungwe (AFRO), Wilfred Nkhoma (AFRO), Eugene Nyarko (AFRO), Henriette Wembanyama (DR Congo).

The Americas: Ademir Albuquerque (Brazil), José Ramón Cruz (AMRO), Rodolfo Rodriguez Cruz (AMRO), Mario Martinez (Brazil), Dionne Patz (AMRO), Pilar Ramon-Pardo (AMRO).

Eastern Mediterranean Region: Samiha Baghdadi (EMRO), Laura Gillini (EMRO), Keiko Inaba (Afghanistan), John Jabbour (EMRO), Giampaolo Mezzabotta (Afghanistan), Akihiro Seita (EMRO), Emanuele Tacconi (Afghanistan).

European Region: Irina Danilova (Russian Federation), Lucica Ditiu (TB Office Balkans), Wieslaw Jakubowiak, Konstantin Malakhov (the Russian Federation), Kestutis Miskinis (TB Office Ukraine), Jerod Scholten (EURO), Gombogaram Tsogt (TB Office Central Asia), Richard Zaleskis (EURO).

South-East Asia Region: Marijke Becx-Bleumink (Bangladesh), Christian Gunneberg (Nepal), Reuben Granich (India), Firdosi Mehta (Indonesia), Nani Nair (SEARO), Jai Narain (SEARO), Myo Paing (Myanmar), Franky Loprang (Indonesia), Emanuele Pontali (SEARO), Fraser Wares (SEARO).

Western Pacific Region: Dongil Ahn (WPRO), Maarten Bosman (Viet Nam), Daniel Chin (China), Pratap Jayavanth (Cambodia), Pieter van Maaren (WPRO), Wang Lixia (China).

The primary aim of this report is to share information from national TB control programmes. The data presented here are supplied largely by programme managers, who have been instrumental in driving much of the work on surveillance, planning, and financing. We thank all of them, and their staff, for their contributions. WHO's Global TB Monitoring and Surveillance Project is carried out with the financial backing of USAID. The DOTS Expansion Project is supported by funding from the governments of Australia, Belgium, Germany, Ireland, the Netherlands, Norway, Switzerland, United Kingdom, and USA. Data for the European Region were collected and validated jointly with EuroTB, a dedicated European TB surveillance network funded by the European Commission. We wish to thank Andrea Infuso and Dennis Falzon of EuroTB for their collaboration. We also thank Pam Baillie, Sue Hobbs, and Keith Wynn for once again doing everything necessary to get this report published by 24 March, World TB Day.

Copies of *Global Tuberculosis Control* are available for sale from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (email: bookorders@who.int) and online at www.who.int/gtb/publications/globrep

Abbreviations

ACD	Afghan Committee for Development	DRS	Drug resistance surveillance
ADB	Asian Development Bank	EMR	WHO Eastern Mediterranean Region
AFB	Acid fast bacilli	EMRO	WHO Regional Office for the Eastern Mediterranean
AFR	WHO African Region	EQA	External quality assurance
AFRO	WHO Regional Office for Africa	EU	European Union
AIDS	Acquired immunodeficiency syndrome	EUR	WHO European Region
ALERT	All Africa Leprosy, TB, and Rehabilitation Training Centre	EURO	WHO Regional Office for Europe
ALM	American Leprosy Mission	FDC	Fixed-dose combination
ALTI	Aide au Lépreux et Tuberculeux de l'Ituri	FHI	Family Health International
AMR	WHO Region of the Americas	FILHA	Finnish Lung and Health Association
AMRO	WHO Regional Office for the Americas	GDF	Global Drug Facility
ART	Anti-retroviral therapy	GFATM	Global Fund to Fight AIDS, TB and Malaria
BRAC	Bangladesh Rural Advancement Committee	GLC	Green Light Committee
CCM	Country Coordinating Mechanism	GLRA	German Leprosy Relief Association
CDC GAP	Centers for Disease Control Global AIDS Program, USA	GMS	German Medical Service
CDC LIFE	Centers for Disease Control Leadership and Investment in Fighting an Epidemic	GNI	Gross national income
CDC	Centers for Disease Control and Prevention, USA	GoJ	Government of Japan
CDR	Case detection rate (i.e. smear-positive case detection rate, whole country)	GTZ	Deutsche Gesellschaft für Technische Zusammenarbeit (German development agency)
CENAT	Centre National Anti-Tuberculeux	HBC	High-burden country of which there are 22 that account for approximately 80% of all new TB cases arising each year
CHC	Community health centre	HIV	Human immunodeficiency virus
CI	Confidence interval	HR	Human resource
CIDA	Canadian International Development Agency	HRDP	Human resource development plan
COMBI	Communication for Behavioural Impact	HSDP	Health Sector Development Programme
DANIDA	Danish International Development Agency	ICC	Interagency Coordinating Committee
DARE	District AIDS and Reproductive Health Project (Kenya)	IEC	Information, Education, Communication
DDR	DOTS detection rate (i.e. smear-positive case detection rate under DOTS)	IFRC	International Federation of Red Cross and Red Crescent Societies
DFB	Damien Foundation Belgium	IUATLD	International Union Against Tuberculosis and Lung Disease
DFID	UK Department for International Development	JATA	Japan Anti-Tuberculosis Association
DoH	Department of Health	JICA	Japan International Cooperation Agency
DOT	Directly observed treatment	JSI	John Snow, Inc.
DOTS	The internationally recommended control strategy for TB	KIL TB	Kings College, Imperial College, and London School of Hygiene & Tropical Medicine TB Consortium
		KNCV	Royal Netherlands Tuberculosis Association

LEPCO	Tuberculosis and Leprosy Control (A German NGO)	PIH	Partners in Health
LEPRA	The British Leprosy Relief Association	PPM	Public-private mix
LGA	Local Government Areas	QA	Quality assurance
LHL	Norwegian Lung and Heart Association	SAPP II	Social Action Programme, Project II (Pakistan)
LMI	Leprosy Mission International	SARS	Severe Acute Respiratory Syndrome
MCNV	Medical Committee Netherlands-Viet Nam	SEAR	WHO South-East Asia Region
MDR	Multidrug resistance	SEARO	WHO Regional Office for South-East Asia
MDR-TB	Multidrug-resistant tuberculosis	STD	Sexually transmitted disease
MEDAIR	An international humanitarian aid organization	STI	Sexually transmitted infection
MERLIN	Medical Emergency Relief International	TB	Tuberculosis
MoH	Ministry of Health	TBCTA	Tuberculosis Coalition for Technical Assistance
MoPH	Ministry of Public Health	TBL	Tuberculosis and leprosy
MoU	Memorandum of understanding	TLMI	The Leprosy Mission International
MSF	Médecins Sans Frontières	UNAIDS	Joint United Nations Programme on HIV/AIDS
NGO	Nongovernmental organization	UNDP	United Nations Development Programme
NHLS	National Health Laboratory Services	USAID	United States Agency for International Development
NICC	National Interagency Coordinating Committee	VCT	Voluntary counselling and testing
NLR	Netherlands Leprosy Relief	WFP	World Food Programme
NORAD	Norwegian Agency for Development	WHO	World Health Organization
NPO	National programme officer	WHO-CHOICE	Choosing Interventions that are Cost-Effective, a WHO project
NTP	National Tuberculosis Control Programme	WPR	WHO Western Pacific Region
PAHO	Pan-American Health Organization	WPRO	WHO Regional Office for the Western Pacific
PHC	Primary Health Care		
PHILCAT	Philippines Coalition against TB		
PHRI	Public Health Research Institute		